First Manhattan’s Corcept Therapeutics CORT Stock Holding History

First Manhattan’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,000	Closed	-$19K	–	1580
2021 Q3	$19K	Hold	1,000	–	–	﹤0.01%	1174
2021 Q2	$22K	Hold	1,000	–	–	﹤0.01%	1144
2021 Q1	$23K	Hold	1,000	–	–	﹤0.01%	1111
2020 Q4	$26K	Hold	1,000	–	–	﹤0.01%	1008
2020 Q3	$17K	Hold	1,000	–	–	﹤0.01%	1043
2020 Q2	$16K	Hold	1,000	–	–	﹤0.01%	1074
2020 Q1	$11K	Buy	+1,000	New	+$12.4K	﹤0.01%	1118

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

First Manhattan's CORT Position: Q4 2021 in Review

First Manhattan sold out of Corcept Therapeutics (CORT) in Q4 2021, closing a stake of 1,000 shares — an estimated $19K sold.

First Manhattan first reported a position in CORT in Q1 2020 and held it in 7 quarters. The position peaked at $26K in Q4 2020. 208 funds tracked by Wall St. Rank hold CORT as of Q4 2021.

First Manhattan reported no remaining Corcept Therapeutics position as of Q4 2021 after selling out during the quarter.
First Manhattan sold 1,000 Corcept Therapeutics shares in Q4 2021, an estimated $19K.
First Manhattan first reported a position in Corcept Therapeutics in Q1 2020 and held it in 7 quarters.
First Manhattan's Corcept Therapeutics position peaked at $26K in Q4 2020.
208 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2021.

Based on First Manhattan's 13F filing for Q4 2021, filed 14 Feb 2022.